Introduction

This chapter covers the management of early stage ER positive HER2 negative breast cancer, detailing a case study and the standard of care including chemotherapy and adjuvant anti-estrogen therapy. It also delves into the Natalie trial investigating the impact of adding adjuvant ribocyclib to endocrine therapy for better outcomes.